The Most Effective Method for Quitting Smoking That Almost Nobody Uses

Varenicline (Champix) has the highest smoking cessation success rate of any approach but is rarely the first thing offered to smokers. Here is the treatment hierarchy and why it matters.

Tobacco use kills approximately 8 million people annually — a toll that exceeds COVID-19 deaths at pandemic peak, every year. Cessation is the single most impactful health improvement that a smoker can make. And the most effective pharmacological approach to cessation — varenicline (marketed as Champix in Europe and Chantix in the US) — achieves approximately double the abstinence rates of nicotine replacement therapy alone at 12 months, yet is rarely the first cessation approach offered by healthcare providers.

Varenicline's mechanism is specific and elegant: it is a partial agonist at the nicotinic acetylcholine receptors that nicotine activates. Partial agonism means it activates the receptor enough to reduce withdrawal symptoms and cravings (the agonist function) while simultaneously blocking nicotine from activating the same receptor if a cigarette is smoked (the antagonist function). This dual mechanism makes it simultaneously a craving-reducer and a reward-blocker — smoking while on varenicline produces less satisfaction, reducing the reinforcement that drives continued smoking.

The 12-month abstinence rates across clinical trials: varenicline alone achieves approximately 25-30 percent continuous abstinence at 12 months. Combination nicotine replacement therapy (patch plus short-acting NRT) achieves approximately 15-25 percent. Bupropion achieves approximately 15-20 percent. Nicotine patch alone achieves approximately 10-15 percent. Brief advice from a healthcare provider (the most commonly provided intervention) achieves approximately 5-10 percent. The hierarchy is clear, and the most effective intervention is the least commonly used.

The reason for the mismatch: varenicline requires a prescription (unlike over-the-counter nicotine replacement), its side effects (primarily nausea and vivid dreams) make some patients discontinue it, and the historical safety concern about psychiatric side effects (which led to a black box warning that has since been revised in the US based on evidence that the risk was not confirmed at the scale initially feared) reduced prescriber enthusiasm. For most smokers without severe psychiatric comorbidity, the risk-benefit calculation strongly favours varenicline over other approaches.